Switch to:
Also traded in: Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.54
CYBX's Cash to Debt is ranked lower than
74% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYBX: 0.54 )
Ranked among companies with meaningful Cash to Debt only.
CYBX' s Cash to Debt Range Over the Past 10 Years
Min: 0.54  Med: 16.06 Max: 25573
Current: 0.54
0.54
25573
Equity to Asset 0.70
CYBX's Equity to Asset is ranked higher than
61% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CYBX: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
CYBX' s Equity to Asset Range Over the Past 10 Years
Min: -0.14  Med: 0.78 Max: 0.94
Current: 0.7
-0.14
0.94
Z-Score: 2.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.46
CYBX's Operating margin (%) is ranked lower than
60% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. CYBX: -9.46 )
Ranked among companies with meaningful Operating margin (%) only.
CYBX' s Operating margin (%) Range Over the Past 10 Years
Min: -47.98  Med: 17.60 Max: 30.81
Current: -9.46
-47.98
30.81
Net-margin (%) -12.18
CYBX's Net-margin (%) is ranked lower than
62% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. CYBX: -12.18 )
Ranked among companies with meaningful Net-margin (%) only.
CYBX' s Net-margin (%) Range Over the Past 10 Years
Min: -47.85  Med: 17.37 Max: 46.76
Current: -12.18
-47.85
46.76
ROE (%) -6.30
CYBX's ROE (%) is ranked lower than
59% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. CYBX: -6.30 )
Ranked among companies with meaningful ROE (%) only.
CYBX' s ROE (%) Range Over the Past 10 Years
Min: -147.26  Med: 22.46 Max: 581.59
Current: -6.3
-147.26
581.59
ROA (%) -4.52
CYBX's ROA (%) is ranked lower than
56% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. CYBX: -4.52 )
Ranked among companies with meaningful ROA (%) only.
CYBX' s ROA (%) Range Over the Past 10 Years
Min: -47.04  Med: 18.26 Max: 58.59
Current: -4.52
-47.04
58.59
ROC (Joel Greenblatt) (%) -17.39
CYBX's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. CYBX: -17.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYBX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -209.55  Med: 100.49 Max: 122.23
Current: -17.39
-209.55
122.23
Revenue Growth (3Y)(%) 15.50
CYBX's Revenue Growth (3Y)(%) is ranked higher than
85% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. CYBX: 15.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYBX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.7  Med: 15.50 Max: 183.9
Current: 15.5
1.7
183.9
EBITDA Growth (3Y)(%) 19.80
CYBX's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CYBX: 19.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYBX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.2  Med: 4.10 Max: 24.8
Current: 19.8
-54.2
24.8
EPS Growth (3Y)(%) 7.00
CYBX's EPS Growth (3Y)(%) is ranked higher than
55% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. CYBX: 7.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYBX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.2  Med: -2.35 Max: 12.2
Current: 7
-38.2
12.2
» CYBX's 10-Y Financials

Financials (Next Earnings Date: 2016-06-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

CYBX Guru Trades in

CYBX Guru Trades in

CYBX Guru Trades in

Q1 2016

CYBX Guru Trades in Q1 2016

Steven Cohen 50,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:PEN, NAS:WMGI, NYSE:NVRO, NYSE:GMED, OTCPK:IOBCF, OTCPK:NHNKY, NAS:CNMD, OTCPK:SHWGF, NAS:BABY, NAS:MASI, NAS:CYNO, NAS:LDRH, OTCPK:GGNDF, NAS:ZLTQ, OTCPK:BSNRF, NYSE:GB, OTCPK:EKTAY, NAS:INGN, OTCPK:SKUNF, NAS:MDXG » details
Traded in other countries:LIA.Germany, LIVN.UK,
LivaNova PLC is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation.

LivaNova PLC was incorporated on February 20, 2015. It is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. The Company transforms medical innovation into solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.

Ratios

vs
industry
vs
history
Forward P/E 17.42
CYBX's Forward P/E is ranked higher than
83% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. CYBX: 17.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.28
CYBX's P/B is ranked higher than
78% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. CYBX: 1.28 )
Ranked among companies with meaningful P/B only.
CYBX' s P/B Range Over the Past 10 Years
Min: 1.28  Med: 1.48 Max: 6.11
Current: 1.28
1.28
6.11
P/S 4.12
CYBX's P/S is ranked lower than
63% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. CYBX: 4.12 )
Ranked among companies with meaningful P/S only.
CYBX' s P/S Range Over the Past 10 Years
Min: 4.12  Med: 5.06 Max: 7.62
Current: 4.12
4.12
7.62
PFCF 27.17
CYBX's PFCF is ranked higher than
54% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.37 vs. CYBX: 27.17 )
Ranked among companies with meaningful PFCF only.
CYBX' s PFCF Range Over the Past 10 Years
Min: 18.33  Med: 26.84 Max: 33.1
Current: 27.17
18.33
33.1
POCF 22.77
CYBX's POCF is ranked lower than
58% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. CYBX: 22.77 )
Ranked among companies with meaningful POCF only.
CYBX' s POCF Range Over the Past 10 Years
Min: 16.87  Med: 23.19 Max: 27.73
Current: 22.77
16.87
27.73
Shiller P/E 54.06
CYBX's Shiller P/E is ranked lower than
61% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.52 vs. CYBX: 54.06 )
Ranked among companies with meaningful Shiller P/E only.
CYBX' s Shiller P/E Range Over the Past 10 Years
Min: 54.07  Med: 62.05 Max: 78.04
Current: 54.06
54.07
78.04
Current Ratio 1.79
CYBX's Current Ratio is ranked lower than
73% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. CYBX: 1.79 )
Ranked among companies with meaningful Current Ratio only.
CYBX' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 5.55 Max: 15.71
Current: 1.79
0.81
15.71
Quick Ratio 1.24
CYBX's Quick Ratio is ranked lower than
73% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. CYBX: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
CYBX' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 4.83 Max: 15.35
Current: 1.24
0.69
15.35
Days Inventory 242.70
CYBX's Days Inventory is ranked lower than
76% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. CYBX: 242.70 )
Ranked among companies with meaningful Days Inventory only.
CYBX' s Days Inventory Range Over the Past 10 Years
Min: 191.44  Med: 249.62 Max: 348.71
Current: 242.7
191.44
348.71
Days Sales Outstanding 241.83
CYBX's Days Sales Outstanding is ranked lower than
94% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. CYBX: 241.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYBX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.89  Med: 56.80 Max: 65.59
Current: 241.83
48.89
65.59
Days Payable 304.36
CYBX's Days Payable is ranked higher than
92% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. CYBX: 304.36 )
Ranked among companies with meaningful Days Payable only.
CYBX' s Days Payable Range Over the Past 10 Years
Min: 47.42  Med: 95.87 Max: 155.13
Current: 304.36
47.42
155.13

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.04
CYBX's Price/Tangible Book is ranked lower than
68% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. CYBX: 6.04 )
Ranked among companies with meaningful Price/Tangible Book only.
CYBX' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.35  Med: 6.85 Max: 7.68
Current: 6.04
6.35
7.68
Price/Projected FCF 1.18
CYBX's Price/Projected FCF is ranked higher than
77% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. CYBX: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
CYBX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.85  Med: 1.34 Max: 1.85
Current: 1.18
0.85
1.85
Price/Median PS Value 0.81
CYBX's Price/Median PS Value is ranked higher than
69% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. CYBX: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
CYBX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.92  Med: 1.15 Max: 1.49
Current: 0.81
0.92
1.49
Earnings Yield (Greenblatt) (%) -1.80
CYBX's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CYBX: -1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYBX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 0.80 Max: 2.8
Current: -1.8
0.7
2.8
Forward Rate of Return (Yacktman) (%) 7.22
CYBX's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 7.22 vs. CYBX: 7.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CYBX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.1  Med: 6.60 Max: 17
Current: 7.22
6.1
17

More Statistics

Revenue (TTM) (Mil) $435.5
Short Percentage of Float7.18%
52-Week Range $48.19 - 76.48
Shares Outstanding (Mil)26.00
» More Articles for CYBX

Headlines

Articles On GuruFocus.com
John Paulson Trims Time Warner Cable, Starwood Hotels May 18 2016 
Cyberonics Inc. (CYBX) President & CEO Daniel Jeffrey Moore sells 44,700 Shares Jan 13 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 10,000 Shares Jan 12 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 5,000 Shares Dec 08 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 22 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Aug 26 2010 
Cyberonics Inc. Reports Operating Results (10-K) Jun 17 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Feb 18 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 19 2009 
Carl Icahn Buys Motorola Inc., Pride International Inc., Anadarko Petroleum Corp., Sells Take-Two In Jun 12 2007 

More From Other Websites
Hedge Funds Are Selling Carrizo Oil & Gas, Inc. (CRZO) Nov 27 2015
Hedge Funds Like What They See From Cyberonics, Inc. (CYBX) Nov 23 2015
CYBERONICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Oct 19 2015
CYBERONICS INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 16 2015
Cyberonics, Inc.: A look at fundamentals : October 16, 2015 Oct 16 2015
Cyberonics-Sorin Appoint LivaNova Members Ahead of Merger Oct 12 2015
ETF’s with exposure to Cyberonics, Inc. : October 9, 2015 Oct 09 2015
Sorin And Cyberonics Announce Appointment Of Remaining Post-Merger Directors Of Combined Company Oct 09 2015
Sorin And Cyberonics Announce Appointment Of Remaining Post-Merger Directors Of Combined Company Oct 09 2015
Cyberonics, Inc. breached its 50 day moving average in a Bullish Manner : October 8, 2015 Oct 08 2015
Cyberonics Set to Join the S&P MidCap 400; Ruckus Wireless to Join S&P SmallCap 600 Oct 05 2015
5 Top-Ranked Stocks with High Returns, Low Debt Oct 02 2015
Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are... Sep 28 2015
Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are... Sep 28 2015
New Strong Buy Stocks for September 25th Sep 25 2015
Cyberonics Investors Okay Sorin Deal; LivaNova Coming Up Sep 24 2015
High Court of England and Wales Issues Order Approving Completion of Merger of Sorin S.P.A. with and... Sep 23 2015
High Court Of England And Wales Issues Order Approving Completion Of Merger Of Sorin S.p.A. With And... Sep 23 2015
CYBERONICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other... Sep 22 2015
Cyberonics Stockholders Overwhelmingly Approve Merger With Sorin Sep 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)